Shandong Company Profile

What is the competitive landscape for SHANDONG

SHANDONG has sixteen approved drugs.

There are five US patents protecting SHANDONG drugs. There are two tentative approvals on SHANDONG drugs.

There are twenty-nine patent family members on SHANDONG drugs in fourteen countries and fifty-six supplementary protection certificates in thirteen countries.

Summary for Shandong

International Patents:	29
US Patents:	5
Tradenames:	14
Ingredients:	14
NDAs:	16

Drugs and US Patents for Shandong

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shandong Luye	RYKINDO	risperidone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212849-003	Jan 13, 2023		RX	Yes	No	9,532,991		Y
Shandong	ROCURONIUM BROMIDE	rocuronium bromide	INJECTABLE;INJECTION	215684-001	Jul 12, 2024	AP	RX	No	No
Shandong	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	204959-001	Aug 10, 2018	AP	RX	No	No
Shandong Xinhua	IBUPROFEN	ibuprofen	TABLET;ORAL	202413-001	Nov 23, 2016	AB	RX	No	No
Shandong	OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	219765-001	Jan 15, 2026	AP	RX	No	No
Shandong Luye	RYKINDO	risperidone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212849-001	Jan 13, 2023		DISCN	Yes	No	9,446,135		Y
Shandong	ISOSORBIDE MONONITRATE	isosorbide mononitrate	TABLET, EXTENDED RELEASE;ORAL	214115-002	Feb 8, 2024	AB	RX	No	No

International Patents for Shandong Drugs

Country	Patent Number	Estimated Expiration
Poland	2701687
China	104127385
Canada	2832663
European Patent Office	2701687
Hungary	E066287
Hungary	E046004
Russian Federation	2013147949

Supplementary Protection Certificates for Shandong Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	122014000088	Germany		PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912
1003503	C01003503/01	Switzerland		PRODUCT NAME: AMLODIPIN + ATORVASTATIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57633 05.07.2006
0196132	94C0008	Belgium		PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
2059246	C202430051	Spain		PRODUCT NAME: UNA COMBINACION DE (A) MACITENTAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y (B) TADALAFILO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/24/1859; DATE OF AUTHORISATION: 20240927; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/24/1859; DATE OF FIRST AUTHORISATION IN EEA: 20240927
0716606	C00716606/01	Switzerland		PRODUCT NAME: SEVELAMER; REGISTRATION NUMBER/DATE: SWISSMEDIC 56297 10.02.2004
0521471	C300125	Netherlands		PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
0716606	6/2002	Austria		PRODUCT NAME: SEVELAMER SOWIE DESSEN PHARMAZEUTISCH VERTRAEGLICHEN SALZE; REGISTRATION NO/DATE: EU/1/99/123/001 - EU/1/99/123/004 20000128

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Shandong
• Shandong Luye
• Shandong Xinhua
• Shanghai Hengrui